Intellia reports 98% reduction in HAE attacks with lonvo-z over 3 years in Phase 1

Intellia Therapeutics, Inc.

Single dose led to mean 98% reduction in monthly HAE attack rate across all 10 patients.
All patients attack-free and treatment-free for median 23 months at data cutoff.
No treatment-emergent serious adverse events; infusional reactions mostly Grade 1, all resolved.
Phase 3 HAELO trial screening completed ahead of schedule; >50% screened in U.S.
Expects BLA submission in 2026 and U.S. launch in 2027, pending FDA approval.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.